本頁面由Tiger Trade Technology Pte. Ltd.提供服務

康乃德生物醫藥

2.04
-0.0200-0.97%
盤後2.03-0.0100-0.49%19:58 EDT
成交量:87.80萬
成交額:177.91萬
市值:1.28億
市盈率:-1.71
高:2.10
開:2.07
低:1.94
收:2.06
52周最高:3.82
52周最低:1.23
股本:6,296.39萬
流通股本:2,106.61萬
量比:0.48
換手率:4.17%
股息:- -
股息率:- -
每股收益(TTM):-1.1933
每股收益(LYR):-1.0000
淨資產收益率:-140.51%
總資產收益率:-69.75%
市淨率:4.78
市盈率(LYR):-2.04

資料載入中...

2023/02/13

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2023/02/13

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2023/01/03

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/07/01

SEC問詢函

CORRESP [Cover] - Correspondence
2022/07/01

員工持股計劃

S-8 - Securities to be offered to employees in employee benefit plans
2022/06/17

SEC問詢函

CORRESP [Cover] - Correspondence
2022/05/20

SEC問詢函

CORRESP [Cover] - Correspondence
2022/03/31

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/02/25

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/02/25

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/02/15

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2022/02/14

超過5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2021/06/07

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2021/03/29

超過5%披露

SC 13D - General statement of acquisition of beneficial ownership
2021/03/19

員工持股計劃

S-8 - Securities to be offered to employees in employee benefit plans
2021/03/18

[修訂]招股説明書

F-1/A [Amend] - Registration statement for certain foreign private issuers
2021/03/17

SEC問詢函

CORRESP [Cover] - Correspondence
2021/03/17

[修訂]招股説明書

F-1/A [Amend] - Registration statement for certain foreign private issuers
2021/03/16

SEC問詢函

CORRESP [Cover] - Correspondence
2021/03/16

SEC問詢函

CORRESP [Cover] - Correspondence